Background-Coronary artery disease (CAD) is highly prevalent in patients undergoing transcatheter aortic valve replacement.
T he use of transcatheter aortic valve replacement (TAVR) for the treatment of severe symptomatic aortic stenosis has grown exponentially during the past decade, with >24 000 procedures performed yearly in the United States alone. 1 Still, TAVR is a complex and costly procedure, associated with mortality rates up to 25% at 1-year and >60% at 5-year follow-up, 2 mainly attributed to the considerable comorbidity burden typical of the TAVR population. Coronary artery disease (CAD) is unique among these comorbidities-it is highly prevalent in the TAVR population (≈50% in large registries and up to 75% in the PARTNER 1 trial [Placement of Aortic Transcatheter Valves trial]) [3] [4] [5] and, perhaps more importantly, it is potentially more amenable to treatment compared with most recognized predictors of post-TAVR mortality, such as frailty, 6 renal function, 7 obstructive lung disease and atrial fibrillation, 8 thus offering a chance for pre-TAVR intervention that may improve post-TAVR outcomes. Early trials that examined the prognostic effect of CAD in the TAVR population found that CAD is not associated with increased mortality post-TAVR, a finding that is somewhat surprising, given the recognized benefits of revascularization in the overall CAD population, 9, 10 as well as in patients undergoing surgical aortic valve replacement. 11 One explanation for this is the heterogeneous nature of CAD, and thus later trials, mainly single center studies, stratified TAVR patients according to CAD severity, mainly using the SYNTAX score (Synergy Between PCI With Taxus and Cardiac Surgery)-yielding conflicting results. Over the recent years, the first multicenter studies on this issue were published, again, yielding conflicting results.
12-14 A more clinically relevant question is not whether CAD (perhaps from a certain severity threshold) exerts a negative effect on post-TAVR survival but rather is more complete coronary revascularization associated with improved prognosis compared with a less complete/no revascularization. To answer this questions, several trials used the residual SYNTAX score (rSS) to stratify patients with CAD undergoing TAVR and again reported conflicting results. A small meta-analysis on this issue (2 trials, 899 patients overall) did not find more complete revascularization to be associated with improved 30-day outcomes post-TAVR. 15 Our objective was to conduct an updated systematic review and meta-analysis on the impact of revascularization completeness (as expressed by the rSS) and on overall survival in patients with both CAD and aortic stenosis undergoing TAVR.
Methods
The data, analytic methods, and study materials will be made available to other researchers by direct contact with the corresponding author for purposes of reproducing the results or replicating the procedure.
The registered study protocol is available on PROSPERO (CRD42017060014). We searched Medline, Embase, and Cochrane CENTRAL from January 1, 2005, up to July 31, 2017, using a combination of keywords and MeSH terms for transcatheter aortic valve replacement AND revascularization with no restrictions on language. We also searched all references of included studies.
Studies examining the impact of coronary revascularization in patients undergoing TAVR were considered for inclusion if they met the following criteria:
1. Comparing outcomes of patients undergoing TAVR according to their anatomic extent of disease, quantified by the rSS, the best validated tool for assessment of revascularization completeness. 16, 17 2. Comparing outcomes of patients with CAD undergoing TAVR stratified according to prespecified rSS threshold and comparing outcomes of patients with CAD above/below an rSS threshold to outcomes of patients without CAD undergoing TAVR. 3. Reporting on all-cause mortality. 4 . Duration of follow-up of at least 6 months.
All titles and abstracts were screened, and those thought to possibly meet the inclusion criteria were screened for eligibility using the full text.
Two reviewers (G.W., O.Z.) independently extracted the data and resolved conflicts by discussion and consensus. Outcome data were extracted for the largest patient population evaluated. The outcome of this meta-analysis was all-cause mortality at the longest available follow-up for each included study.
Two authors assessed the risk of bias (G.W., O.Z.). The NewcastleOttawa tool was used to assess the quality of studies. 18 The reviewers resolved conflicts through consensus.
A funnel plot was used to assess publication bias.
A systematic review and meta-analysis were performed in compliance with the Cochrane Collaboration and Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement. 19 Metaanalysis was performed using the Review Manager (RevMan) software (version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).
The outcome of this meta-analysis was all-cause mortality. We performed 4 sets of comparisons:
1. Patients with no CAD versus CAD patients with high rSS. 2. Patients with no CAD versus CAD patients with low rSS.
3. CAD patients with low rSS versus CAD patients with high rSS. 4. Patients with no CAD+CAD patients with low rSS versus CAD patients with high rSS. We adopted the rSS threshold used in each study to assign patients into the high/low rSS groups. Patients in the high rSS group are referred to as having received incomplete revascularization (ICR) before TAVR and those in the low rSS group as having received reasonable ICR.
Heterogeneity between the included trials was assessed using the χ 2 test for heterogeneity and the I 2 measure of inconsistency, 20 but the choice between a random/fixed effect model was not determined by the results of statistical tests for heterogeneity, but rather, as recently recommended by a scientific statement of the American Heart Association, 21 by evaluating the functional similarity between the included studies and the goal of estimating a common effect size that will be applicable to similar populations to those included in this meta-analysis. For fixed effects, pooled estimates of odds ratio (OR) with 95% confidence intervals (CI) were calculated using the Mantel-Haenszel method. For random effects, the DerSimonian and Laird random method was used. Reported values are 2 tailed, and hypothesis-testing results were considered significant at P<0.05.
Results
The results of the study selection process are shown in Figure 1. Our initial search yielded 59 citations, of which 20 were judged to be potentially eligible and underwent full text review. Six studies (total of 3110 patients) were found to be eligible for inclusion after full text review. [12] [13] [14] [22] [23] [24] All were observational studies, 2 multicenter and 4 single center studies. Follow-up period ranged from 0.7 to 3 years. All the studies were ranked as good quality according to the Newcastle-Ottawa tool (all received a score of 8). The characteristics of the studies included in this meta-analysis are shown in the Table. The baseline characteristics of the patients, stratified by CAD status and CAD severity (according to the SYNTAX score), are shown in Table I in the Data Supplement.
Because the study by Khawaja et al 22 did not report specifically on patients with reasonable ICR, but rather only on patients with no CAD, no CAD/reasonable ICR, and ICR, so it was not included in the analyses comparing reasonable ICR versus ICR and reasonable ICR versus no CAD. The study by Van Miegham et al 24 did not report on outcomes of patients with no CAD, so its results were included only in the analysis of reasonable ICR versus ICR.
WHAT IS KNOWN
• Current data suggest that patients with severe coronary artery disease (as defined by the SYNTAX score [Synergy Between PCI With Taxus and Cardiac Surgery]) are at increased risk for mortality post-transcatheter aortic valve replacement.
WHAT THE STUDY ADDS
• Out results suggest that more complete revascularization pre-transcatheter aortic valve replacement (as assessed by the residual SYNTAX score) mitigated the increased risk exerted by coronary artery disease in patients undergoing transcatheter aortic valve replacement.
• Our results suggest that in the transcatheter aortic valve replacement population, revascularization achieving a residual SYNTAX score <8 is equivalent to complete anatomic revascularization in terms of long-term mortality (similar to what is known in the overall coronary artery disease population).
Because all the studies were similar in terms of study design and the population studied, we used a fixed effects model in all analyses.
The effect of revascularization completeness on post-TAVR mortality is shown in Figures 2 to 4 .
Compared with patients with no CAD, ICR was associated with an increased risk for mortality (OR, 1.85; 95% CI, The 2 studies with the largest sample size, together containing 1931/3110 (63%) of the overall sample size in this meta-analysis, reported on adjusted analysis. In both studies, 13 Because the rSS for the definition of ICR was not the same in all the studies, we conducted a subgroup analysis restricted to the 4 studies with a consistent definition of ICR (8 for three 12, 14, 24 and 9 for the fourth study 22 ) for our main comparison-overall mortality for patients with no CAD/reasonable ICR versus ICR: the results of the subgroup analysis were consistent with that of the main analysis (OR, 1.78; 95% CI, 1.23-2.56; P<0.001 for the subgroup of studies with consistent definition of ICR compared with OR, 1.71; 95% CI, 
Discussion
The results of our meta-analysis suggest that in patients with both CAD and severe aortic stenosis undergoing TAVR, the degree of pre-TAVR revascularization completeness (as assessed by the rSS) has a significant prognostic impact. Although patients with CAD who receive reasonable ICR before TAVR have a similar mortality risk to those with no CAD, those who do not have an ≈2-fold increased risk for mortality compared with those with no CAD. The same applies within the CAD group itself-patients receiving reasonable ICR show a 41% lower risk for mortality compared with those with ICR. These findings are in line with current data in the general CAD population, in which reasonable ICR (as determined by rSS <8) is associated with similar outcomes to complete revascularization, while ICR is associated with increased mortality 16 and suggest that the rSS is a useful tool for determining both the need as well as the optimal level of coronary revascularization in patients with CAD undergoing TAVR.
The robust clinical data showing that CAD per se is not an independent predictor of post-TAVR mortality 3, 25 are probably explained by 2 factors:
1. The heterogeneous nature of CAD, resulting in a dilution of its prognostic effect, when pooling patients across the full spectrum of disease severity and comparing them, as a whole, to those with no CAD. This is especially relevant remembering that although CAD is prevalent in the TAVR population, most of these patients have lowintermediate severity CAD (as assessed by the SYNTAX score). 2. The advanced age and considerable comorbidities burden of TAVR patients that result in ≈50% of deaths in this population being of noncardiovascular cause 8 practically serving as a competing risk and negating the prognostic effect of CAD. This is why, if we truly want to examine the prognostic effect of CAD in TAVR patients, it is imperative that we do so with stratification by disease severity. Focusing on patients in the most severe CAD stratum allows us to identify those who are expected to be at the most increased risk for CAD-related mortality and indeed most 13, 14, 22, 23, 26 though not all 12,27,28 studies that used the SYNTAX score showed a worse prognosis for the highest severity patients with CAD. From a clinical perspective, the most relevant question is not whether severe CAD is associated with increased mortality but rather whether appropriate and timely revascularization may mitigate this increased risk. To answer this question, stratifying patients with CAD using the SYNTAX score is inadequate because it does not take into account the possibility of pre-TAVR revascularization, and hence the most appropriate measure is the rSS, which reflects the completeness of revascularization pre-TAVR. There is one previous meta-analysis that examined the prognostic effect of the rSS in TAVR patients, 15 and it included only 2 single center studies 23, 24 and did not find an rSS <10 to be associated with improved outcomes at 30-day followup compared with higher rSS. The authors acknowledged the limitation of their small sample size and the need for more data on this issue. In this sense, our meta-analysis marks a significant improvement-it includes 4 additional studies, 12-14,22 2 of whom are multicenter studies-reaching an overall sample size >3-fold greater (3107 compared with 899 patients), the follow-up periods ranged from 0.7 to 3 years (with 5/6 studies having a follow-up period of at least 1 year).
We therefore think that our results showing an ≈2-fold increased mortality in patients with ICR should be acknowledged as a novel finding that should be taken into account by physicians evaluating and assessing TAVR candidates. The effect of ICR on mortality is similar if not greater to that of well-recognized mortality predictors post-TAVR (as reported recently in a 5-year follow-up results of a large national all comers TAVR registry), such as frailty, residual moderate+aortic regurgitation, renal failure, low valve gradients pre-TAVR, and atrial fibrillation, 29 but unlike these factors, the level of revascularization completeness is, at least potentially, modifiable. Our results suggest that adequate revascularization pre-TAVR may offer a unique and significant opportunity to improve the prognosis of patients with CAD undergoing TAVR-a finding that is relevant to ≈50% of TAVR patients. 3 A point worth mentioning is that over recent years, the profile of TAVR patients is changing, and as evidence accumulates of the benefit of TAVR for patients at intermediate surgical risk, 30, 31 the fraction of patients <80 years old is growing steadily, 1 and this may increase the relative importance and significance of CAD among the myriad of comorbidities in the TAVR population as the life expectancy of younger TAVR patients is expected to increase, which will allow untreated CAD to exert an even more significant effect on survival on the one hand and possibly enhance the benefits of adequate revascularization on the other hand.
Our study has several limitations: it includes only observational studies (the first randomized trial on the effect of revascularization in TAVR patients-the ACTIVATION trial 32 is ongoing) with most reporting on results without adjustment, so there remains the possibility that the increased mortality risk in the ICR patients is because of confounding by indication; the definition of ICR (eg, high rSS) was not the same in all the trials, so we cannot directly address the important and clinically relevant question of the optimal definition of reasonable ICR in the TAVR population. Having said that in 4/6 studies, 12, 14, 22, 24 it was practically identical (8 or 9) and consistent with the accepted definition in the overall CAD population (eg, rSSs >8), 16 we conducted a subgroup analysis restricted to these trials, whose results were consistent with those of the overall results ( Figure II in the Data Supplement), which suggests that this definitions may be suitable to the TAVR population as well. As mentioned above, only 2 studies reported multivariate-adjusted HR for mortality, but they represented >60% of the sample size of this meta-analysis, and their results were again consistent with the results of the overall analysis (HR of 1.6 and 1.7, for the comparison of ICR versus no CAD/reasonable ICR [1.7 and 1.6]compared with an OR of 1.71 for the similar comparison in our meta-analysis). None of the studies examined the related and relevant issue of the optimal timing for pre-TAVR revascularization (staged/concomitant). We did not assess any other outcomes other than mortality and did not separate cardiovascular from noncardiovascular mortality.
Conclusions
Our results suggest that for patients with CAD undergoing TAVR, reasonable ICR may carry significant benefits in terms of mortality. Adequate revascularization may offer a unique and valuable opportunity to improve the prognosis of these patients. More data from future studies are needed to better guide the assessment and preparation of patients with CAD before TAVR in an attempt to achieve optimal outcomes in this subset of patients, which totals ≈50% of patients undergoing TAVR.
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